Taro Pharmaceutical Industries Ltd. (TARO)
Jun 24, 2024 - TAR was delisted (reason: acquired by Sun Pharma)
42.97
0.00 (0.00%)
Inactive · Last trade price on Jun 21, 2024
TARO Revenue
In the fiscal year ending March 31, 2024, Taro Pharmaceutical Industries had annual revenue of $629.18M with 9.81% growth. Taro Pharmaceutical Industries had revenue of $164.94M in the quarter ending March 31, 2024, with 12.52% growth.
Revenue (ttm)
$629.18M
Revenue Growth
+9.81%
P/S Ratio
2.57
Revenue / Employee
$404,879
Employees
1,554
Market Cap
1.62B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 629.18M | 56.23M | 9.81% |
Mar 31, 2023 | 572.95M | 11.61M | 2.07% |
Mar 31, 2022 | 561.35M | 12.38M | 2.25% |
Mar 31, 2021 | 548.97M | -95.80M | -14.86% |
Mar 31, 2020 | 644.77M | -25.12M | -3.75% |
Mar 31, 2019 | 669.89M | 7.98M | 1.21% |
Mar 31, 2018 | 661.91M | -217.47M | -24.73% |
Mar 31, 2017 | 879.39M | -71.36M | -7.51% |
Mar 31, 2016 | 950.75M | 87.81M | 10.18% |
Mar 31, 2015 | 862.94M | 103.66M | 13.65% |
Mar 31, 2014 | 759.29M | 88.33M | 13.16% |
Mar 31, 2013 | 670.95M | 127.87M | 23.55% |
Mar 31, 2012 | 543.08M | 37.41M | 7.40% |
Dec 31, 2011 | 505.67M | 113.13M | 28.82% |
Dec 31, 2010 | 392.54M | 36.60M | 10.28% |
Dec 31, 2009 | 355.94M | 26.90M | 8.18% |
Dec 31, 2008 | 329.04M | 9.48M | 2.97% |
Dec 31, 2007 | 319.55M | 67.29M | 26.67% |
Dec 31, 2006 | 252.27M | -36.35M | -12.60% |
Dec 31, 2005 | 288.62M | 17.64M | 6.51% |
Dec 31, 2004 | 270.99M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionTARO News
- 1 year ago - Sun Pharma Completes Taro Merger - PRNewsWire
- 1 year ago - Taro Shareholders Approve Merger with Sun Pharma - PRNewsWire
- 1 year ago - Taro Provides Results for Year Ended March 31, 2024 - Business Wire
- 1 year ago - Taro to Release Full Year Results on May 20, 2024 - Business Wire
- 1 year ago - Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote “FOR” Taro Sun Pharma Merger - Business Wire
- 1 year ago - TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro Pharmaceutical Industries Ltd. - TARO - Business Wire
- 1 year ago - Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd. - Business Wire
- 1 year ago - Krensavage Asset Management Remains Opposed to Sun's Predatory Bid for Taro - PRNewsWire